On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs in Modernaﾒs pipeline, at Catalentﾒs biologics facility in Bloomington, Indiana.

Catalent dedicated to Modernaﾒs use a new high-speed filling line at the site through Jun. 2023, which can be used to manufacture the COVID-19 vaccine and potentially additional investigational programs in Modernaﾒs large clinical pipeline.